UNSPSC 51161883: Tetrahydrozoline

This classification denotes an alpha-adrenergic agonist with the molecular formula C13H16N2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier S9U025Y077, chemically known as 4,5-dihydro-2-(1,2,3,4-tetrahydro-1-naphthalenyl)-1h-imidazole but more generally known as tetrahydrozoline, which bears U.S. National Institutes of Health Compound Identifier 5419. The European Medicines Agency schedules Tetryzoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10955MIG.

The term TETRYZOLINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13, No. 12, 1959, List 3). The World Health Organization schedules tetrahydrozoline in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: C1CC(C2=CC=CC=C2C1)C3=NCCN3.

UNSPSC 51161883 Tetrahydrozoline is a Commodity code that encompasses pharmaceutical products, though the recent state and local solicitations tagged with this code show activity in broader pharmaceutical and over-the-counter product procurement rather than tetrahydrozoline specifically. State and local governments buy generic pharmaceuticals, OTC products, and emergency medical supplies (including naloxone and drug deactivation systems) through this code, with procurement driven by public health departments, county health systems, and cooperative purchasing alliances serving multiple jurisdictions. Issuing bodies include county health agencies and multistate cooperative purchasing consortiums that aggregate demand across participating states and local government facilities.

The code shows activity centered in Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023 (note: deadline date appears inconsistent with posting date); the contract includes a two-year initial term with one-year renewal option and is potentially FEMA-funded. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026; evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and administrative fee agreement, requiring cGMP and Drug Supply Chain Security Act certification and relationships with specified wholesalers.